Bezuclastinib

Gastrointestinal stromal tumor

Manufacturer: Cogent Biosciences
Regulatory submission: NDA submitted April 2026
Launch: Anticipated in the second half of 2026
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment

Current treatment options and standard of care

11 evidence topics · 9 sources

Active surveillance1 evidence topic · 1 source
Surgical resection1 evidence topic · 1 source
KIT and PDGFRA tyrosine kinase inhibitors4 evidence topics · 5 sources
TRK inhibitors1 evidence topic · 1 source
mTOR inhibitor and tyrosine kinase inhibitor combinations1 evidence topic · 1 source
Ablative therapies1 evidence topic · 1 source
Radiotherapy1 evidence topic · 1 source
Limitations of current therapies1 evidence topic · 3 sources